Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 16Prostatic Neoplasms 4Neoplasms 4Carcinoma, Intraductal, Noninfiltrating 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Peripheral Nervous System Diseases 2Pain 2Lung Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Cardiovascular Diseases 2Breast Carcinoma In Situ 2Arthralgia 2Weight Loss 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma 1Radiation Injuries 1Psoriasis 1Polyps 1Polycystic Ovary Syndrome 1Pelvic Inflammatory Disease 1Ovarian Neoplasms 1Osteoarthritis 1Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Escitalopram 3Psilocybin 2Interpersonal Psychotherapy 2Infliximab 2Antidepressive Agents 2abacavir 1Vortioxetine 1Venlafaxine Hydrochloride 1Transcranial Magnetic Stimulation 1Sugars 1Saline Solution 1Mirtazapine 1Magnetic Resonance Spectroscopy 1Ketamine 1Fatty Acids, Omega-3 1Diagnostic Imaging 1Desvenlafaxine Succinate 1Cognitive Behavioral Therapy 1Citalopram 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Depressive Disorder, Major × Fatty Acids, Omega-3 × Clear all
NCT01803711 2017-12-27

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

UConn Health

Phase 2/3 Terminated
6 enrolled 4 charts

Cardiovascular Diseases, Depression, Depressive Disorder, Major, Diabetes Mellitus, Hypertension, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡